The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry
Biomanufacturing company Amyris has announced it will acquire Oobli, a fellow US-based food-tech company that produces fermentation-derived sweet protein ingredients.
The acquisition will bring together Amyris’ scientific and manufacturing capabilities with Oobli’s protein fermentation expertise. Both companies are headquartered in California, with complementary activities in the biotech space.
Amyris creates speciality molecules for a range of industries, including food flavours and fragrances, beauty and personal care, and more. Founded in 2003, it uses advanced fermentation technology to create customised ingredients that aim to boost product performance.
Meanwhile, Oobli uses its proprietary technology platform to create non-GMO sweet proteins that can help F&B companies significantly reduce sugar without sacrificing taste.
Sweet proteins are originally found in fruits and berries near the equator, and are digested as protein, but taste like sugar. They bind directly to sweet taste receptors and are metabolised by the body as protein, delivering sweetness without gut disruption or blood sugar spikes.
The proteins’ intense sweetness – generally hundreds to thousands of times sweeter than sugar, depending on the variety – means they can be used in food and beverage formulations in very small quantities, helping contribute to the industry’s wider sugar reduction goals in line with efforts to improve public health.
Kathy Fortmann, CEO of Amyris, said: “Oobli is poised to transform how sweetness makes it to market, and we are thrilled to bring our commercial scale and resources to further accelerate the sweet revolution”.
“Further, by bringing Oobli's protein expertise together with our strain engineering, manufacturing scale and commercial capabilities, we see the potential to broaden our capabilities in food and beverage, personal care, flavour and fragrances, agriculture and beyond, expanding the ways we can help customers innovate.”
Oobli’s portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit sweet proteins (scientifically known as brazzein, monellin and thaumatin, respectively). The solutions have achieved US Food and Drug Administration Generally Recognized as Safe (GRAS) status, GRAS-affirmed for use as a natural flavour across different applications including sports nutrition, dairy, beverages, chocolate and confectionery, and bakery.
The acquisition follows Amyris’ manufacturing capacity expansion earlier this year at its advanced fermentation facility in Barra Bonita, Brazil. The latest move marks the company’s continued technology and commercial expansion, growing Amyris’ presence in the protein- and peptide-based solution space.
The acquisition, the financial terms of which were not disclosed, is expected to close in the coming weeks. Amyris said that all existing customer commitments and brand partnerships will continue to be honoured uninterrupted.
Ali Wing, CEO of Oobli, said: “It Oobli, we have always believed there was a better way to deliver the sweet taste consumers love, without the trade-offs to health and our environment. It is with immense pride that we look back on the breakthroughs we have achieved.”
“Joining forces with Amyris gives us the scale and resources to realise our ambition of making sweet proteins the global standard in sweetness solutions. Sweet proteins are an idea whose time is now.”










